作为新型利钠肽受体1（NPR1）激活剂的氢喹唑啉衍生物
Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) Activators.
作者信息
Zhou Xin, Liang Steven H
机构信息
Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.
出版信息
ACS Med Chem Lett. 2025 Jan 23;16(3):358-360. doi: 10.1021/acsmedchemlett.5c00013. eCollection 2025 Mar 13.
Abstract
This patent highlights hydroquinazoline compounds and their pharmaceutically acceptable salts, as well as compositions and methods of preparation. The compounds in this invention were evaluated for their potency on Natriuretic Peptide Receptor 1 (NPR1), a receptor guanylate cyclase known to play a critical role in lowering blood pressure and blood volume.
摘要
该专利着重介绍了氢喹唑啉化合物及其药学上可接受的盐，以及组合物和制备方法。本发明中的化合物针对利钠肽受体1（NPR1）的活性进行了评估，NPR1是一种受体鸟苷酸环化酶，已知在降低血压和血容量方面发挥关键作用。
相似文献
1
Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) Activators.
ACS Med Chem Lett. 2025 Jan 23;16(3):358-360. doi: 10.1021/acsmedchemlett.5c00013. eCollection 2025 Mar 13.
2
Natriuretic peptides modulate monocyte-derived Langerhans cell differentiation and promote a migratory phenotype.
Front Immunol. 2025 Jun 9;16:1593141. doi: 10.3389/fimmu.2025.1593141. eCollection 2025.
3
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
4
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
5
Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods.
Front Pharmacol. 2025 Jun 10;16:1501330. doi: 10.3389/fphar.2025.1501330. eCollection 2025.
6
Nitazenes: review of comparative pharmacology and antagonist action.
Clin Toxicol (Phila). 2025 Jun;63(6):393-406. doi: 10.1080/15563650.2025.2504133. Epub 2025 May 27.
7
Gender differences in the context of interventions for improving health literacy in migrants: a qualitative evidence synthesis.
Cochrane Database Syst Rev. 2024 Dec 12;12(12):CD013302. doi: 10.1002/14651858.CD013302.pub2.
8
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.
Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. doi: 10.1002/14651858.CD014513.
9
Patient experiences of partnering with healthcare professionals for hand hygiene compliance: a systematic review.
JBI Database System Rev Implement Rep. 2017 Jun;15(6):1645-1670. doi: 10.11124/JBISRIR-2016-003001.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
本文引用的文献
1
Cardiac cGMP Regulation and Therapeutic Applications.
Hypertension. 2025 Feb;82(2):185-196. doi: 10.1161/HYPERTENSIONAHA.124.21709. Epub 2024 Dec 11.
2
New and future heart failure drugs.
Nat Cardiovasc Res. 2024 Dec;3(12):1389-1407. doi: 10.1038/s44161-024-00576-z. Epub 2024 Dec 4.
3
C-type natriuretic peptide (CNP): The cardiovascular system and beyond.
Pharmacol Ther. 2024 Oct;262:108708. doi: 10.1016/j.pharmthera.2024.108708. Epub 2024 Aug 21.
4
The Impact of Natriuretic Peptides on Heart Development, Homeostasis, and Disease.
Cells. 2024 May 28;13(11):931. doi: 10.3390/cells13110931.
5
New therapeutic targets in hypertension.
Med Clin (Barc). 2024 Sep 27;163(6):301-305. doi: 10.1016/j.medcli.2024.03.028. Epub 2024 Jun 6.
6
Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure.
Can J Physiol Pharmacol. 2001 Aug;79(8):730-5.
Zotero 插件